EuroAPI

EAPI.PAPre-clinical

Paris, FranceFounded 2022euroapi.com

EuroAPI is a France-based, publicly traded company focused on reinventing active ingredient solutions to meet global customer and patient needs sustainably. It operates with a dual business model: supplying a broad portfolio of established APIs and offering specialized CDMO services for novel therapeutics. The company's mission is to secure the healthcare value chain by providing high-quality, sustainable API solutions, supported by a global industrial footprint serving over 80 countries.

Market Cap

$143.3M

Founded

2022

Focus

Small MoleculesDrug Manufacturing

EAPI.PA · Stock Price

USD 1.3012.21 (-90.34%)

Historical price data

AI Company Overview

Technology Platform

Integrated manufacturing platform for small molecule Active Pharmaceutical Ingredients (APIs), encompassing complex chemical synthesis, microbial fermentation, and advanced CDMO services for oligonucleotides, lipids, and particle engineering.

Funding History

Total raised: $200M

IPO$200MUndisclosedMay 6, 2022

Opportunities

EuroAPI is poised to benefit from the strategic trend towards healthcare sovereignty in Europe, demanding secure regional API supply.

The rapid growth in advanced therapeutics (oligonucleotides, mRNA) creates significant demand for its high-tech CDMO services in lipids and Tides.

Furthermore, the ongoing wave of small-molecule patent expiries fuels demand for complex generic APIs, an area of strength.

Risk Factors

The company faces intense pricing pressure in its established API business from lower-cost global competitors.

Its growth depends on successfully executing and scaling the competitive CDMO business.

Operational risks include potential supply chain disruptions, regulatory compliance issues across its large manufacturing network, and exposure to volatile energy and raw material costs.

Competitive Landscape

EuroAPI competes with large API merchants like Siegfried and Asian manufacturers, as well as diversified CDMOs like Lonza and Catalent. Its differentiation lies in its unique combination of one of the world's largest API portfolios, a secure European manufacturing footprint, and specialized CDMO expertise in high-growth niches like oligonucleotides and lipid nanoparticles.